Andrew Reardon, serving as both Chief Legal Officer and Secretary for Ligand Pharmaceuticals Inc., executed a significant stock sale on July 1, 2026, totaling $1,566,376. The transaction involved the disposal of 5,000 shares of the company's common stock, conducted under the parameters of a pre-arranged Rule 10b5-1 trading plan. The shares were liquidated at prices fluctuating between $308.63 and $317.43 per unit.
This divestment activity occurs as Ligand Pharmaceuticals trades in close proximity to its 52-week peak of $320.99. Over the preceding twelve months, the stock has generated a substantial 179% return. Current market data places the share price at $320.42, with valuations suggesting the stock may be trading above its fair value threshold.
Before the execution of the sale, Reardon had engaged in acquisition activities on the same date. He purchased 5,000 shares through the exercise of employee stock options, priced at $52.27 per share, amounting to $261,350. This acquisition was also facilitated under a Rule 10b5-1 plan. Additionally, on June 30, 2026, he acquired 132 shares at $160.7095 each via the Ligand Employee Stock Purchase Plan.
Corporate developments at Ligand Pharmaceuticals include a first-quarter 2026 earnings report that fell short of market expectations. Adjusted earnings per share were recorded at $1.63, missing the projected $1.84. Revenue similarly underperformed, coming in at $51.72 million against a forecast of $59.07 million.
Financially, Ligand completed a $700 million convertible notes offering, which included $75 million in additional notes purchased by initial buyers. This resulted in net proceeds of approximately $678.2 million. This offering follows a prior announcement regarding the pricing of $625 million in convertible senior notes due in 2031.
Strategically, Ligand Pharmaceuticals amended its merger agreement with XOMA Royalty Corporation. The revision incorporates XOMA Royalty Holdings Corporation as a party to the agreement. Under the updated structure, Flex Merger Sub, Inc., a wholly owned subsidiary of Ligand, will merge with and into the newly formed HoldCo.